Recent studies highlight that TIM-3 is highly expressed in NSCLC tumor tissues and significantly associated with nodal metastasis, advanced disease stages, and reduced overall survival, positioning TIM-3 as an attractive therapeutic target (Gao et al., 2012; Sauer et al., 2023). This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.